Table of Contents Author Guidelines Submit a Manuscript
International Journal of Cell Biology
Volume 2012, Article ID 930710, 11 pages
http://dx.doi.org/10.1155/2012/930710
Review Article

GSK-3 𝜷 : A Bifunctional Role in Cell Death Pathways

1Department of Radiation Oncology, Washington University in St. Louis, St. Louis, MO 63108, USA
2School of Medcine, Washington University in St. Louis, St. Louis, MO 63108, USA
3Siteman Cancer Center, St. Louis, MO 63110, USA
4Mallinckrodt Institute of Radiology, St. Louis, MO 63110, USA

Received 6 January 2012; Revised 9 March 2012; Accepted 12 March 2012

Academic Editor: Paolo Pinton

Copyright © 2012 Keith M. Jacobs et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Frame and P. Cohen, “GSK3 takes centre stage more than 20 years after its discovery,” Biochemical Journal, vol. 359, no. 1, pp. 1–16, 2001. View at Publisher · View at Google Scholar · View at Scopus
  2. B. W. Doble and J. R. Woodgett, “GSK-3: tricks of the trade for a multi-tasking kinase,” Journal of Cell Science, vol. 116, no. 7, pp. 1175–1186, 2003. View at Publisher · View at Google Scholar · View at Scopus
  3. R. S. Jope and G. V. W. Johnson, “The glamour and gloom of glycogen synthase kinase-3,” Trends in Biochemical Sciences, vol. 29, no. 2, pp. 95–102, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. C. A. Grimes and R. S. Jope, “The multifaceted roles of glycogen synthase kinase 3β in cellular signaling,” Progress in Neurobiology, vol. 65, no. 4, pp. 391–426, 2001. View at Publisher · View at Google Scholar · View at Scopus
  5. J. Luo, “Glycogen synthase kinase 3β (GSK3β) in tumorigenesis and cancer chemotherapy,” Cancer Letters, vol. 273, no. 2, pp. 194–200, 2009. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Pap and G. M. Cooper, “Role of translation initiation factor 2B in control of cell survival by the phosphatidylinositol 3-kinase/Akt/glycogen synthase kinase 3β signaling pathway,” Molecular and Cellular Biology, vol. 22, no. 2, pp. 578–586, 2002. View at Publisher · View at Google Scholar · View at Scopus
  7. J. F. Sanchez, L. F. Sniderhan, A. L. Williamson, S. Fan, S. Chakraborty-Sett, and S. B. Maggirwar, “Glycogen synthase kinase 3β-mediated apoptosis of primary cortical astrocytes involves inhibition of nuclear factor κB signaling,” Molecular and Cellular Biology, vol. 23, no. 13, pp. 4649–4662, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. P. Cohen and S. Frame, “The renaissance of GSK3,” Nature Reviews Molecular Cell Biology, vol. 2, no. 10, pp. 769–776, 2001. View at Publisher · View at Google Scholar · View at Scopus
  9. E. M. Yazlovitskaya, E. Edwards, D. Thotala et al., “Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation,” Cancer Research, vol. 66, no. 23, pp. 11179–11186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. E. Ter Haar, J. T. Coll, D. A. Austen, H. M. Hsiao, L. Swenson, and J. Jain, “Structure of GSK3β reveals a primed phosphorylation mechanism,” Nature Structural Biology, vol. 8, no. 7, pp. 593–596, 2001. View at Publisher · View at Google Scholar · View at Scopus
  11. R. Dajani, E. Fraser, S. M. Roe et al., “Crystal structure of glycogen synthase kinase 3β: structural basis for phosphate-primed substrate specificity and autoinhibition,” Cell, vol. 105, no. 6, pp. 721–732, 2001. View at Publisher · View at Google Scholar · View at Scopus
  12. D. A. E. Cross, D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings, “Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B,” Nature, vol. 378, no. 6559, pp. 785–789, 1995. View at Publisher · View at Google Scholar · View at Scopus
  13. H. Eldar-Finkelman, R. Seger, J. R. Vandenheede, and E. G. Krebs, “Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells,” Journal of Biological Chemistry, vol. 270, no. 3, pp. 987–990, 1995. View at Publisher · View at Google Scholar · View at Scopus
  14. L. Kim, J. Liu, and A. R. Kimmel, “The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification,” Cell, vol. 99, no. 4, pp. 399–408, 1999. View at Google Scholar · View at Scopus
  15. R. V. Bhat, S. L. Budd Haeberlein, and J. Avila, “Glycogen synthase kinase 3: a drug target for CNS therapies,” Journal of Neurochemistry, vol. 89, no. 6, pp. 1313–1317, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. F. Hernández, M. Pérez, J. J. Lucas, A. M. Mata, R. Bhat, and J. Avila, “Glycogen synthase kinase-3 plays a crucial role in tau exon 10 splicing and intranuclear distribution of SC35: implications for Alzheimer's disease,” Journal of Biological Chemistry, vol. 279, no. 5, pp. 3801–3806, 2004. View at Publisher · View at Google Scholar · View at Scopus
  17. T. A. Fulga, I. Elson-Schwab, V. Khurana et al., “Abnormal bundling and accumulation of F-actin mediates tau-induced neuronal degeneration in vivo,” Nature Cell Biology, vol. 9, no. 2, pp. 139–148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. P. Cohen and M. Goedert, “GSK3 inhibitors: development and therapeutic potential,” Nature Reviews Drug Discovery, vol. 3, no. 6, pp. 479–487, 2004. View at Google Scholar · View at Scopus
  19. E. S. Emamian, D. Hall, M. J. Birnbaum, M. Karayiorgou, and J. A. Gogos, “Convergent evidence for impaired AKT1-GSK3β signaling in schizophrenia,” Nature Genetics, vol. 36, no. 2, pp. 131–137, 2004. View at Publisher · View at Google Scholar · View at Scopus
  20. J. M. Beaulieu, T. D. Sotnikova, W. D. Yao et al., “Lithium antagonizes dopamine-dependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 14, pp. 5099–5104, 2004. View at Publisher · View at Google Scholar · View at Scopus
  21. P. S. Klein and D. A. Melton, “A molecular mechanism for the effect of lithium on development,” Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 16, pp. 8455–8459, 1996. View at Publisher · View at Google Scholar · View at Scopus
  22. A. P. Kozikowski, I. N. Gaisina, P. A. Petukhov et al., “Highly potent and specific GSK-3β inhibitors that block tau phosphorylation and decrease α-synuclein protein expression in a cellular model of Parkinson's disease,” ChemMedChem, vol. 1, no. 2, pp. 256–266, 2006. View at Publisher · View at Google Scholar · View at Scopus
  23. L. Wang, H. K. Lin, Y. C. Hu, S. Xie, L. Yang, and C. Chang, “Suppression of androgen receptor-mediated transactivation and cell growth by the glycogen synthase kinase 3β in prostate cells,” Journal of Biological Chemistry, vol. 279, no. 31, pp. 32444–32452, 2004. View at Publisher · View at Google Scholar · View at Scopus
  24. A. Shakoori, A. Ougolkov, W. Y. Zhi et al., “Deregulated GSK3β activity in colorectal cancer: its association with tumor cell survival and proliferation,” Biochemical and Biophysical Research Communications, vol. 334, no. 4, pp. 1365–1373, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. A. Shakoori, W. Mai, K. Miyashita et al., “Inhibition of GSK-3β activity attenuates proliferation of human colon cancer cells in rodents,” Cancer Science, vol. 98, no. 9, pp. 1388–1393, 2007. View at Publisher · View at Google Scholar · View at Scopus
  26. A. V. Ougolkov, M. E. Fernandez-Zapico, D. N. Savoy, R. A. Urrutia, and D. D. Billadeau, “Glycogen synthase kinase-3β participates in nuclear factor κB-mediated gene transcription and cell survival in pancreatic cancer cells,” Cancer Research, vol. 65, no. 6, pp. 2076–2081, 2005. View at Publisher · View at Google Scholar · View at Scopus
  27. E. Beurel and R. S. Jope, “The paradoxical pro- and anti-apoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways,” Progress in Neurobiology, vol. 79, no. 4, pp. 173–189, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. J. R. Miller and R. T. Moon, “Signal transduction through β-catenin and specification of cell fate during embryogenesis,” Genes and Development, vol. 10, no. 20, pp. 2527–2539, 1996. View at Google Scholar · View at Scopus
  29. M. Peifer and P. Polakis, “Wnt signaling in oncogenesis and embryogenesis—a look outside the nucleus,” Science, vol. 287, no. 5458, pp. 1606–1609, 2000. View at Publisher · View at Google Scholar · View at Scopus
  30. R. H. Giles, J. H. Van Es, and H. Clevers, “Caught up in a Wnt storm: Wnt signaling in cancer,” Biochimica et Biophysica Acta, vol. 1653, no. 1, pp. 1–24, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. J. A. Diehl, M. Cheng, M. F. Roussel, and C. J. Sherr, “Glycogen synthase kinase-3β regulates cyclin D1 proteolysis and subcellular localization,” Genes and Development, vol. 12, no. 22, pp. 3499–3511, 1998. View at Google Scholar · View at Scopus
  32. G. N. Bijur, P. De Sarno, and R. S. Jope, “Glycogen synthase kinase-3β facilitates staurosporine- and heat shock- induced apoptosis. Protection by lithium,” Journal of Biological Chemistry, vol. 275, no. 11, pp. 7583–7590, 2000. View at Publisher · View at Google Scholar · View at Scopus
  33. J. E. Forde and T. C. Dale, “Glycogen synthase kinase 3: a key regulator of cellular fate,” Cellular and Molecular Life Sciences, vol. 64, no. 15, pp. 1930–1944, 2007. View at Publisher · View at Google Scholar · View at Scopus
  34. P. Watcharasit, G. N. Bijur, J. W. Zmijewski et al., “Direct, activating interaction between glycogen synthase kinase-3β and p53 after DNA damage,” Proceedings of the National Academy of Sciences of the United States of America, vol. 99, no. 12, pp. 7951–7955, 2002. View at Publisher · View at Google Scholar · View at Scopus
  35. R. D. Loberg, E. Vesely, and F. C. Brosius, “Enhanced glycogen synthase kinase-3β activity mediates hypoxia-induced apoptosis of vascular smooth muscle cells and is prevented by glucose transport and metabolism,” Journal of Biological Chemistry, vol. 277, no. 44, pp. 41667–41673, 2002. View at Publisher · View at Google Scholar · View at Scopus
  36. L. Song, P. De Sarno, and R. S. Jope, “Central role of glycogen synthase kinase-3β in endoplasmic reticulum stress-induced caspase-3 activation,” Journal of Biological Chemistry, vol. 277, no. 47, pp. 44701–44708, 2002. View at Publisher · View at Google Scholar · View at Scopus
  37. J. Carmichael, K. L. Sugars, Y. P. Bao, and D. C. Rubinsztein, “Glycogen synthase kinase-3β inhibitors prevent cellular polyglutamine toxicity caused by the Huntington's disease mutation,” Journal of Biological Chemistry, vol. 277, no. 37, pp. 33791–33798, 2002. View at Publisher · View at Google Scholar · View at Scopus
  38. D. A. E. Cross, A. A. Culbert, K. A. Chalmers, L. Facci, S. D. Skaper, and A. D. Reith, “Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death,” Journal of Neurochemistry, vol. 77, no. 1, pp. 94–102, 2001. View at Publisher · View at Google Scholar · View at Scopus
  39. E. M. Yazlovitskaya, E. Edwards, D. Thotala et al., “Lithium treatment prevents neurocognitive deficit resulting from cranial irradiation,” Cancer Research, vol. 66, no. 23, pp. 11179–11186, 2006. View at Publisher · View at Google Scholar · View at Scopus
  40. A. A. Culbert, M. J. Brown, S. Frame et al., “GSK-3 inhibition by adenoviral FRAT1 overexpression is neuroprotective and induces Tau dephosphorylation and β-catenin stabilisation without elevation of glycogen synthase activity,” FEBS Letters, vol. 507, no. 3, pp. 288–294, 2001. View at Publisher · View at Google Scholar · View at Scopus
  41. G. N. Bijur, P. De Sarno, and R. S. Jope, “Glycogen synthase kinase-3β facilitates staurosporine- and heat shock- induced apoptosis. Protection by lithium,” Journal of Biological Chemistry, vol. 275, no. 11, pp. 7583–7590, 2000. View at Publisher · View at Google Scholar · View at Scopus
  42. C. A. Grimes and R. S. Jope, “The multifaceted roles of glycogen synthase kinase 3β in cellular signaling,” Progress in Neurobiology, vol. 65, no. 4, pp. 391–426, 2001. View at Publisher · View at Google Scholar · View at Scopus
  43. M. Oren, “Decision making by p53: life, death and cancer,” Cell Death and Differentiation, vol. 10, no. 4, pp. 431–442, 2003. View at Publisher · View at Google Scholar · View at Scopus
  44. J. P. Kruse and W. Gu, “Modes of p53 Regulation,” Cell, vol. 137, no. 4, pp. 609–622, 2009. View at Publisher · View at Google Scholar · View at Scopus
  45. P. Watcharasit, G. N. Bijur, L. Song, J. Zhu, X. Chen, and R. S. Jope, “Glycogen synthase kinase-3beta (GSK3beta) binds to and promotes the actions of p53,” The Journal of Biological Chemistry, vol. 278, no. 49, pp. 48872–48879, 2003. View at Google Scholar · View at Scopus
  46. E. Beurel, M. Kornprobst, M. J. Blivet-Van Eggelpoël et al., “GSK-3β inhibition by lithium confers resistance to chemotherapy-induced apoptosis through the repression of CD95 (Fas/APO-1) expression,” Experimental Cell Research, vol. 300, no. 2, pp. 354–364, 2004. View at Publisher · View at Google Scholar · View at Scopus
  47. G. A. Turenne and B. D. Price, “Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity,” BMC Cell Biology, vol. 2, 2001. View at Publisher · View at Google Scholar · View at Scopus
  48. O. Pluquet, L. K. Qu, D. Baltzis, and A. E. Koromilas, “Endoplasmic reticulum stress accelerates p53 degradation by the cooperative actions of Hdm2 and glycogen synthase kinase 3β,” Molecular and Cellular Biology, vol. 25, no. 21, pp. 9392–9405, 2005. View at Publisher · View at Google Scholar · View at Scopus
  49. L. Qu, S. Huang, D. Baltzis et al., “Endoplasmic reticulum stress induces p53 cytoplasmic localization and prevents p53-dependent apoptosis by a pathway involving glycogen synthase kinase-3β,” Genes and Development, vol. 18, no. 3, pp. 261–277, 2004. View at Publisher · View at Google Scholar · View at Scopus
  50. T. Y. Eom, K. A. Roth, and R. S. Jope, “Neural precursor cells are protected from apoptosis induced by trophic factor withdrawal or genotoxic stress by inhibitors of glycogen synthase kinase 3,” Journal of Biological Chemistry, vol. 282, no. 31, pp. 22856–22864, 2007. View at Publisher · View at Google Scholar · View at Scopus
  51. G. Arboleda, Y. Cardenas, Y. Rodriguez, L. C. Morales, L. Matheus, and H. Arboleda, “Differential regulation of AKT, MAPK and GSK3beta during C2-ceramide-induced neuronal death,” Neurotoxicology, vol. 31, no. 6, pp. 687–693, 2010. View at Google Scholar
  52. A. Mora, G. Sabio, A. M. Risco et al., “Lithium blocks the PKB and GSK3 dephosphorylation induced by ceramide through protein phosphatase-2A,” Cellular Signalling, vol. 14, no. 6, pp. 557–562, 2002. View at Publisher · View at Google Scholar · View at Scopus
  53. K. T. Noh, Y. M. Park, S. G. Cho, and E. J. Choi, “GSK-3β-induced ASK1 stabilization is crucial in LPS-induced endotoxin shock,” Experimental Cell Research, vol. 317, no. 12, pp. 1663–1668, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. S. Sengupta, P. Jayaraman, P. M. Chilton, C. R. Casella, and T. C. Mitchell, “Unrestrained glycogen synthase kinase-3β activity leads to activated T cell death and can be inhibited by natural adjuvant,” Journal of Immunology, vol. 178, no. 10, pp. 6083–6091, 2007. View at Google Scholar · View at Scopus
  55. Y. J. Kang, M. Digicaylioglu, R. Russo et al., “Erythropoietin plus insulin-like growth factor-I protects against neuronal damage in a murine model of human immunodeficiency virus-associated neurocognitive disorders,” Annals of Neurology, vol. 68, no. 3, pp. 342–352, 2010. View at Publisher · View at Google Scholar · View at Scopus
  56. F. Peng, N. K. Dhillon, H. Yao, X. Zhu, R. Williams, and S. Buch, “Mechanisms of platelet-derived growth factor-mediated neuroprotection—implications in HIV dementia,” European Journal of Neuroscience, vol. 28, no. 7, pp. 1255–1264, 2008. View at Publisher · View at Google Scholar · View at Scopus
  57. Z. Sui, L. F. Sniderhan, S. Fan et al., “Human immunodeficiency virus-encoded Tat activates glycogen synthase kinase-3β to antagonize nuclear factor-κB survival pathway in neurons,” European Journal of Neuroscience, vol. 23, no. 10, pp. 2623–2634, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. O. Goldbaum and C. Richter-Landsberg, “Activation of PP2A-like phosphatase and modulation of tau phosphorylation accompany stress-induced apoptosis in cultured oligodendrocytes,” GLIA, vol. 40, no. 3, pp. 271–282, 2002. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Kihira, A. Suzuki, T. Kondo et al., “Immunohistochemical expression of IGF-I and GSK in the spinal cord of Kii and Guamanian ALS patients: original Article,” Neuropathology, vol. 29, no. 5, pp. 548–558, 2009. View at Publisher · View at Google Scholar · View at Scopus
  60. S. H. Koh, Y. B. Lee, K. S. Kim et al., “Role of GSK-3β activity in motor neuronal cell death induced by G93A or A4V mutant hSOD1 gene,” European Journal of Neuroscience, vol. 22, no. 2, pp. 301–309, 2005. View at Publisher · View at Google Scholar · View at Scopus
  61. M. H. Liang, J. R. Wendland, and D. M. Chuang, “Lithium inhibits Smad3/4 transactivation via increased CREB activity induced by enhanced PKA and AKT signaling,” Molecular and Cellular Neuroscience, vol. 37, no. 3, pp. 440–453, 2008. View at Publisher · View at Google Scholar · View at Scopus
  62. D. F. Martins, A. O. Rosa, V. M. Gadotti et al., “The antinociceptive effects of AR-A014418, a selective inhibitor of glycogen synthase kinase-3 beta, in mice,” Journal of Pain, vol. 12, no. 3, pp. 315–322, 2011. View at Publisher · View at Google Scholar · View at Scopus
  63. M. Pérez, A. I. Rojo, F. Wandosell, J. Díaz-Nido, and J. Avila, “Prion peptide induces neuronal cell death through a pathway involving glycogen synthase kinase 3,” Biochemical Journal, vol. 372, no. 1, pp. 129–136, 2003. View at Publisher · View at Google Scholar · View at Scopus
  64. Z. Tang, P. Arjunan, C. Lee et al., “Survival effect of PDGF-CC rescues neurons from apoptosis in both brain and retina by regulating GSK3β phosphorylation,” Journal of Experimental Medicine, vol. 207, no. 4, pp. 867–880, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. J. M. Gall, V. Wong, D. R. Pimental et al., “Hexokinase regulates Bax-mediated mitochondrial membrane injury following ischemic stress,” Kidney International, vol. 79, no. 11, pp. 1207–1216, 2011. View at Publisher · View at Google Scholar · View at Scopus
  66. Y. Hotokezaka, K. van Leyen, E. H. Lo et al., “AlphaNAC depletion as an initiator of ER stress-induced apoptosis in hypoxia,” Cell Death & Differentiation, vol. 16, no. 11, pp. 1505–1514, 2009. View at Google Scholar
  67. Q. Li, H. Li, K. Roughton et al., “Lithium reduces apoptosis and autophagy after neonatal hypoxia-ischemia,” Cell Death and Disease, vol. 1, no. 7, article e56, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. A. K. Vasileva, E. Y. Plotnikov, A. V. Kazachenko, V. I. Kirpatovsky, and D. B. Zorov, “Inhibition of GSK-3β decreases the ischemia-induced death of renal cells,” Bulletin of Experimental Biology and Medicine, vol. 149, no. 3, pp. 303–307, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. R. Kulikov, K. A. Boehme, and C. Blattner, “Glycogen synthase kinase 3-dependent phosphorylation of Mdm2 regulates p53 abundance,” Molecular and Cellular Biology, vol. 25, no. 16, pp. 7170–7180, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. D. K. Thotala, D. E. Hallahan, and E. M. Yazlovitskaya, “Inhibition of glycogen synthase kinase 3β attenuates neurocognitive dysfunction resulting from cranial irradiation,” Cancer Research, vol. 68, no. 14, pp. 5859–5868, 2008. View at Publisher · View at Google Scholar · View at Scopus
  71. D. K. Thotala, D. E. Hallahan, and E. M. Yazlovitskaya, “Glycogen synthase kinase 3β inhibitors protect hippocampal neurons from radiation-induced apoptosis by regulating MDM2-p53 pathway,” Cell Death and Differentiation, vol. 19, pp. 387–396, 2011. View at Publisher · View at Google Scholar · View at Scopus
  72. R. Lu, L. Song, and R. S. Jope, “Lithium attenuates p53 levels in human neuroblastoma SH-SY5Y cells,” NeuroReport, vol. 10, no. 5, pp. 1123–1125, 1999. View at Google Scholar · View at Scopus
  73. J. W. Zmijewski and R. S. Jope, “Nuclear accumulation of glycogen synthase kinase-3 during replicative senescence of human fibroblasts,” Aging Cell, vol. 3, no. 5, pp. 309–317, 2004. View at Publisher · View at Google Scholar · View at Scopus
  74. R. J. Youle and A. Strasser, “The BCL-2 protein family: opposing activities that mediate cell death,” Nature Reviews Molecular Cell Biology, vol. 9, no. 1, pp. 47–59, 2008. View at Publisher · View at Google Scholar · View at Scopus
  75. G. Lessene, P. E. Czabotar, and P. M. Colman, “BCL-2 family antagonists for cancer therapy,” Nature Reviews Drug Discovery, vol. 7, no. 12, pp. 989–1000, 2008. View at Publisher · View at Google Scholar · View at Scopus
  76. P. Li, D. Nijhawan, I. Budihardjo et al., “Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade,” Cell, vol. 91, no. 4, pp. 479–489, 1997. View at Google Scholar · View at Scopus
  77. D. K. Thotala, L. Geng, A. K. Dickey, D. E. Hallahan, and E. M. Yazlovitskaya, “A New class of molecular targeted radioprotectors: GSK-3β inhibitors,” International Journal of Radiation Oncology Biology Physics, vol. 76, no. 2, pp. 557–565, 2010. View at Publisher · View at Google Scholar · View at Scopus
  78. S. R. Datta, A. Brunet, and M. E. Greenberg, “Cellular survival: a play in three akts,” Genes and Development, vol. 13, no. 22, pp. 2905–2927, 1999. View at Publisher · View at Google Scholar · View at Scopus
  79. A. Dickey, S. Schleicher, K. Leahy, R. Hu, D. Hallahan, and D. K. Thotala, “GSK-3β inhibition promotes cell death, apoptosis, and in vivo tumor growth delay in neuroblastoma Neuro-2A cell line,” Journal of Neuro-Oncology, vol. 104, pp. 145–153, 2010. View at Publisher · View at Google Scholar · View at Scopus
  80. G. P. Meares and R. S. Jope, “Resolution of the nuclear localization mechanism of glycogen synthase kinase-3: functional effects in apoptosis,” Journal of Biological Chemistry, vol. 282, no. 23, pp. 16989–17001, 2007. View at Publisher · View at Google Scholar · View at Scopus
  81. S. Korur, R. M. Huber, B. Sivasankaran et al., “GSK3beta regulates differentiation and growth arrest in glioblastoma,” PloS One, vol. 4, no. 10, article e7443, 2009. View at Google Scholar · View at Scopus
  82. S. Kotliarova, S. Pastorino, L. C. Kovell et al., “Glycogen synthase kinase-3 inhibition induces glioma cell death through c-MYC, nuclear factor-κB, and glucose regulation,” Cancer Research, vol. 68, no. 16, pp. 6643–6651, 2008. View at Publisher · View at Google Scholar · View at Scopus
  83. M. Sun, L. Song, Y. Li, T. Zhou, and R. S. Jope, “Identification of an antiapoptotic protein complex at death receptors,” Cell Death and Differentiation, vol. 15, no. 12, pp. 1887–1900, 2008. View at Publisher · View at Google Scholar · View at Scopus
  84. R. Venè, P. Larghero, G. Arena, M. B. Sporn, A. Albini, and F. Tosetti, “Glycogen synthase kinase 3β regulates cell death induced by synthetic triterpenoids,” Cancer Research, vol. 68, no. 17, pp. 6987–6996, 2008. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Damalas, A. Ben-Ze'ev, I. Simcha et al., “Excess β-catenin promotes accumulation of transcriptionally active p53,” EMBO Journal, vol. 18, no. 11, pp. 3054–3063, 1999. View at Publisher · View at Google Scholar · View at Scopus
  86. E. Sadot, B. Geiger, M. Oren, and A. Ben-Ze'ev, “Down-regulation of β-catenin by activated p53,” Molecular and Cellular Biology, vol. 21, no. 20, pp. 6768–6781, 2001. View at Publisher · View at Google Scholar · View at Scopus
  87. G. P. Meares, M. A. Mines, E. Beurel et al., “Glycogen synthase kinase-3 regulates endoplasmic reticulum (ER) stress-induced CHOP expression in neuronal cells,” Experimental Cell Research, vol. 317, no. 11, pp. 1621–1628, 2011. View at Publisher · View at Google Scholar · View at Scopus
  88. K. P. Hoeflich, J. Luo, E. A. Rubie, M. S. Tsao, O. Jin, and J. R. Woodgett, “Requirement for glycogen synthase kinase-3β in cell survival and NF-κB activation,” Nature, vol. 406, no. 6791, pp. 86–90, 2000. View at Publisher · View at Google Scholar · View at Scopus
  89. F. Demarchi, C. Bertoli, P. Sandy, and C. Schneider, “Glycogen synthase kinase-3β regulates NF-κB1/p105 stability,” Journal of Biological Chemistry, vol. 278, no. 41, pp. 39583–39590, 2003. View at Publisher · View at Google Scholar · View at Scopus
  90. R. F. Schwabe and D. A. Brenner, “Role of glycogen synthase kinase-3 in TNF-α-induced NF-κB activation and apoptosis in hepatocytes,” American Journal of Physiology, vol. 283, no. 1, pp. G204–G211, 2002. View at Google Scholar · View at Scopus
  91. J. Deng, S. A. Miller, H. Y. Wang et al., “β-catenin interacts with and inhibits NF-κB in human colon and breast cancer,” Cancer Cell, vol. 2, no. 4, pp. 323–334, 2002. View at Publisher · View at Google Scholar · View at Scopus
  92. F. Gotschel, C. Kern, S. Lang et al., “Inhibition of GSK3 differentially modulates NF-kappaB, CREB, AP-1 and beta-catenin signaling in hepatocytes, but fails to promote TNF-alpha-induced apoptosis,” Experimental Cell Research, vol. 314, no. 6, pp. 1351–1366, 2008. View at Google Scholar
  93. P. Schotte, G. Van Loo, I. Carpentier, P. Vandenabeele, and R. Beyaert, “Lithium sensitizes tumor cells in an NFκB-independent way to caspase activation and apoptosis induced by tumor necrosis factor (TNF): evidence for a role of the TNF receptor-associated death domain protein,” Journal of Biological Chemistry, vol. 276, no. 28, pp. 25939–25945, 2001. View at Publisher · View at Google Scholar · View at Scopus
  94. X. Liao, L. Zhang, J. B. Thrasher, J. Du, and B. Li, “Glycogen synthase kinase-3beta suppression eliminates tumor necrosis factor-related apoptosis-inducing ligand resistance in prostate cancer.,” Molecular Cancer Therapeutics, vol. 2, no. 11, pp. 1215–1222, 2003. View at Google Scholar · View at Scopus
  95. G. N. Bijur and R. S. Jope, “Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3β,” Journal of Biological Chemistry, vol. 276, no. 40, pp. 37436–37442, 2001. View at Publisher · View at Google Scholar · View at Scopus
  96. F. Takahashi-Yanaga and T. Sasaguri, “GSK-3β regulates cyclin D1 expression: a new target for chemotherapy,” Cellular Signalling, vol. 20, no. 4, pp. 581–589, 2008. View at Publisher · View at Google Scholar · View at Scopus
  97. A. Arcaro and M. P. Wymann, “Wortmannin is a potent phosphatidylinositol 3-kinase inhibitor: the role of phosphatidylinositol 3,4,5-trisphosphate in neutrophil responses,” Biochemical Journal, vol. 296, no. 2, pp. 297–301, 1993. View at Google Scholar · View at Scopus
  98. M. Pap and G. M. Cooper, “Role of glycogen synthase kinase-3 in the phosphatidylinositol 3- kinase/Akt cell survival pathway,” Journal of Biological Chemistry, vol. 273, no. 32, pp. 19929–19932, 1998. View at Publisher · View at Google Scholar · View at Scopus
  99. C. J. Vlahos, W. F. Matter, K. Y. Hui, and R. F. Brown, “A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)- 8-phenyl-4H-1-benzopyran-4-one (LY294002),” Journal of Biological Chemistry, vol. 269, no. 7, pp. 5241–5248, 1994. View at Google Scholar · View at Scopus
  100. S. Arico, S. Pattingre, C. Bauvy et al., “Celecoxib induces apoptosis by inhibiting 3-phosphoinositide-dependent protein kinase-1 activity in the human colon cancer HT-29 cell line,” Journal of Biological Chemistry, vol. 277, no. 31, pp. 27613–27621, 2002. View at Publisher · View at Google Scholar · View at Scopus
  101. M. M. Hill, M. Andjelkovic, D. P. Brazil, S. Ferrari, D. Fabbro, and B. A. Hemmings, “Insulin-stimulated protein kinase B phosphorylation on Ser-473 is independent of its activity and occurs through a staurosporine-insensitive kinase,” Journal of Biological Chemistry, vol. 276, no. 28, pp. 25643–25646, 2001. View at Publisher · View at Google Scholar · View at Scopus
  102. A. R. Hussain, M. Al-Rasheed, P. S. Manogaran et al., “Curcumin induces apoptosis via inhibition of PI3′-kinase/AKT pathway in acute T cell leukemias,” Apoptosis, vol. 11, no. 2, pp. 245–254, 2006. View at Publisher · View at Google Scholar · View at Scopus
  103. F. Meggio, A. Donella Deana, M. Ruzzene et al., “Different susceptibility of protein kinases to staurosporine inhibition. Kinetic studies and molecular bases for the resistance of protein kinase CK2,” European Journal of Biochemistry, vol. 234, no. 1, pp. 317–322, 1995. View at Google Scholar · View at Scopus
  104. A. Noël, L. Barrier, F. Rinaldi, C. Hubert, B. Fauconneau, and S. Ingrand, “Lithium chloride and staurosporine potentiate the accumulation of phosphorylated glycogen synthase kinase 3β/Tyr216, resulting in glycogen synthase kinase 3β activation in SH-SY5Y human neuroblastoma cell lines,” Journal of Neuroscience Research, vol. 89, no. 5, pp. 755–763, 2011. View at Publisher · View at Google Scholar · View at Scopus
  105. J. P. Alao, A. V. Stavropoulou, E. W. F. Lam, and R. C. Coombes, “Role of glycogen synthase kinase 3 beta (GSK3β) in mediating the cytotoxic effects of the histone deacetylase inhibitor trichostatin A (TSA) in MCF-7 breast cancer cells,” Molecular Cancer, vol. 5, article 40, 2006. View at Publisher · View at Google Scholar · View at Scopus
  106. L. Yang, H. C. Dan, M. Sun et al., “Akt/protein kinase B signaling inhibitor-2, a selective small molecule inhibitor of Akt signaling with antitumor activity in cancer cells overexpressing Akt,” Cancer Research, vol. 64, no. 13, pp. 4394–4399, 2004. View at Publisher · View at Google Scholar · View at Scopus
  107. J. Dong, J. Peng, H. Zhang et al., “Role of glycogen synthase kinase 3β in rapamycin-mediated cell cycle regulation and chemosensitivity,” Cancer Research, vol. 65, no. 5, pp. 1961–1972, 2005. View at Publisher · View at Google Scholar · View at Scopus
  108. H. H. Zhang, A. I. Lipovsky, C. C. Dibble, M. Sahin, and B. D. Manning, “S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt,” Molecular Cell, vol. 24, no. 2, pp. 185–197, 2006. View at Publisher · View at Google Scholar · View at Scopus
  109. M. Benkoussa, C. Brand, M. H. Delmotte, P. Formstecher, and P. Lefebvre, “Retinoic acid receptors inhibit AP1 activation by regulating extracellular signal-regulated kinase and CBP recruitment to an AP1-responsive promoter,” Molecular and Cellular Biology, vol. 22, no. 13, pp. 4522–4534, 2002. View at Publisher · View at Google Scholar · View at Scopus
  110. Y. Ma, Q. Feng, D. Sekula, J. A. Diehl, S. J. Freemantle, and E. Dmitrovsky, “Retinoid targeting of different D-type cyclins through distinct chemopreventive mechanisms,” Cancer Research, vol. 65, no. 14, pp. 6476–6483, 2005. View at Publisher · View at Google Scholar · View at Scopus
  111. J. Mori, F. Takahashi-Yanaga, Y. Miwa et al., “Differentiation-inducing factor-1 induces cyclin D1 degradation through the phosphorylation of Thr286 in squamous cell carcinoma,” Experimental Cell Research, vol. 310, no. 2, pp. 426–433, 2005. View at Publisher · View at Google Scholar · View at Scopus
  112. F. Takahashi-Yanaga, Y. Taba, Y. Miwa et al., “Dictyostelium differentiation-inducing factor-3 activates glycogen synthase kinase-3β and degrades cyclin D1 in mammalian cells,” Journal of Biological Chemistry, vol. 278, no. 11, pp. 9663–9670, 2003. View at Publisher · View at Google Scholar · View at Scopus
  113. M. Medina and J. Avila, “Glycogen synthase kinase-3 (GSK-3) inhibitors for the treatment of Alzheimer's disease,” Current Pharmaceutical Design, vol. 16, no. 25, pp. 2790–2798, 2010. View at Google Scholar · View at Scopus
  114. J. Avila and F. Hernández, “GSK-3 inhibitors for Alzheimer's disease,” Expert Review of Neurotherapeutics, vol. 7, no. 11, pp. 1527–1533, 2007. View at Publisher · View at Google Scholar · View at Scopus
  115. G. Klamer, E. Song, K. H. Ko, T. A. O'Brien, and A. Dolnikov, “Using small molecule GSK3β inhibitors to treat inflammation,” Current Medicinal Chemistry, vol. 17, no. 26, pp. 2873–2881, 2010. View at Publisher · View at Google Scholar · View at Scopus
  116. S. Phukan, V. S. Babu, A. Kannoji, R. Hariharan, and V. N. Balaji, “GSK3β: role in therapeutic landscape and development of modulators,” British Journal of Pharmacology, vol. 160, no. 1, pp. 1–19, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. W. J. Ryves, R. Dajani, L. Pearl, and A. J. Harwood, “Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites,” Biochemical and Biophysical Research Communications, vol. 290, no. 3, pp. 967–972, 2002. View at Publisher · View at Google Scholar · View at Scopus
  118. A. Martinez, A. Castro, I. Dorronsoro, and M. Alonso, “Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation,” Medicinal Research Reviews, vol. 22, no. 4, pp. 373–384, 2002. View at Publisher · View at Google Scholar · View at Scopus
  119. M. Aoki, T. Yokota, I. Sugiura et al., “Structural insight into nucleotide recognition in tau-protein kinase I/glycogen synthase kinase 3β,” Acta Crystallographica D, vol. 60, no. 3, pp. 439–446, 2004. View at Publisher · View at Google Scholar · View at Scopus
  120. B. Bax, P. S. Carter, C. Lewis et al., “The structure of phosphorylated GSK-3β complexed with a peptide, FRATtide, that inhibits β-catenin phosphorylation,” Structure, vol. 9, no. 12, pp. 1143–1152, 2001. View at Publisher · View at Google Scholar · View at Scopus
  121. J. A. Bertrand, S. Thieffine, A. Vulpetti et al., “Structural characterization of the GSK-3β active site using selective and non-selective ATP-mimetic inhibitors,” Journal of Molecular Biology, vol. 333, no. 2, pp. 393–407, 2003. View at Publisher · View at Google Scholar · View at Scopus
  122. R. Bhat, Y. Xue, S. Berg et al., “Structural insights and biological effects of glycogen synthase kinase 3-specific inhibitor AR-A014418,” The Journal of Biological Chemistry, vol. 278, no. 46, pp. 45937–45945, 2003. View at Google Scholar
  123. R. Dajani, E. Fraser, S. M. Roe et al., “Structural basis for recruitment of glycogen synthase kinase 3β to the axin-APC scaffold complex,” EMBO Journal, vol. 22, no. 3, pp. 494–501, 2003. View at Publisher · View at Google Scholar · View at Scopus
  124. D. Shin, S. C. Lee, Y. S. Heo et al., “Design and synthesis of 7-hydroxy-1H-benzoimidazole derivatives as novel inhibitors of glycogen synthase kinase-3β,” Bioorganic and Medicinal Chemistry Letters, vol. 17, no. 20, pp. 5686–5689, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. H. C. Zhang, L. V. Bonaga, H. Ye, C. K. Derian, B. P. Damiano, and B. E. Maryanoff, “Novel bis(indolyl)maleimide pyridinophanes that are potent, selective inhibitors of glycogen synthase kinase-3,” Bioorganic & Medicinal Chemistry Letters, vol. 17, no. 10, pp. 2863–2868, 2007. View at Google Scholar
  126. R. S. Jope, “Lithium and GSK-3: one inhibitor, two inhibitory actions, multiple outcomes,” Trends in Pharmacological Sciences, vol. 24, no. 9, pp. 441–443, 2003. View at Publisher · View at Google Scholar · View at Scopus
  127. M. P. Coghlan, A. A. Culbert, D. A. E. Cross et al., “Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription,” Chemistry and Biology, vol. 7, no. 10, pp. 793–803, 2000. View at Publisher · View at Google Scholar · View at Scopus
  128. L. Meijer, A. M. W. H. Thunnissen, A. W. White et al., “Inhibition of cyclin-dependent kinases, GSK-3β and CK1 by hymenialdisine, a marine sponge constituent,” Chemistry and Biology, vol. 7, no. 1, pp. 51–63, 2000. View at Publisher · View at Google Scholar · View at Scopus
  129. D. W. Zaharevitz, R. Gussio, M. Leost et al., “Discovery and initial characterization of the paullones, a novel class of smallmolecule inhibitors of cyclin-dependent kinases,” Cancer Research, vol. 59, no. 11, pp. 2566–2569, 1999. View at Google Scholar · View at Scopus
  130. R. Hoessel, S. Leclerc, J. A. Endicott et al., “Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases,” Nature Cell Biology, vol. 1, no. 1, pp. 60–67, 1999. View at Google Scholar · View at Scopus
  131. S. Leclerc, M. Garnier, R. Hoessel et al., “Indirubins inhibit glycogen synthase kinase-3β and CDK5/P25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors?” Journal of Biological Chemistry, vol. 276, no. 1, pp. 251–260, 2001. View at Publisher · View at Google Scholar · View at Scopus
  132. L. Meijer, A. L. Skaltsounis, P. Magiatis et al., “GSK-3-selective inhibitors derived from tyrian purple indirubins,” Chemistry and Biology, vol. 10, no. 12, pp. 1255–1266, 2003. View at Publisher · View at Google Scholar · View at Scopus
  133. A. Martinez, M. Alonso, A. Castro, C. Pérez, and F. J. Moreno, “First non-ATP competitive glycogen synthase kinase 3 β (GSK-3β) inhibitors: thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease,” Journal of Medicinal Chemistry, vol. 45, no. 6, pp. 1292–1299, 2002. View at Publisher · View at Google Scholar · View at Scopus
  134. M. P. Coghlan, A. A. Culbert, D. A. E. Cross et al., “Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription,” Chemistry and Biology, vol. 7, no. 10, pp. 793–803, 2000. View at Publisher · View at Google Scholar · View at Scopus
  135. G. M. Thomas, S. Frame, M. Goedert, I. Nathke, P. Polakis, and P. Cohen, “A GSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of Axin and β-catenin,” FEBS Letters, vol. 458, no. 2, pp. 247–251, 1999. View at Publisher · View at Google Scholar · View at Scopus